CYTX - Cytori Therapeutics, Inc.


Weak GrowthStock Price Very High


based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -9.81%
Operating Income is Negative
Net Income is Negative but improving
Earnings Per Share (EPS) turning Positive
Net Margin is -67.59%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.03
Debt Ratio is 0.78
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 1.06
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Cytori Therapeutics, Inc. (CYTX) -
Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.
Exchange - NASDAQ
Industry - Biotechnology
Sector - Health Technology
CEO - Marc H. Hedrick
Employees - 37

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.